News

Terreno Realty Reaches Analyst Target Price

TRNO

In recent trading, shares of Terreno Realty Corp (Symbol: TRNO) have crossed above the average analyst 12-month target price of $69.75, changing hands for $70.28/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on

Omada Health Reaches Analyst Target Price

OMDA

In recent trading, shares of Omada Health Inc (Symbol: OMDA) have crossed above the average analyst 12-month target price of $23.33, changing hands for $23.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on val

Bank earnings, Warsh heads to the Hill, Chipotle's Mexico push and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

The AI Boom Isn't Over: 3 Stocks to Buy for 2H 2026

CSCO, MU, NVDA, AMAT

MU, AMAT and CSCO are expanding AI products, partnerships and infrastructure to capitalize on strong demand in 2H 2026.

Warsh promises inflation will be a 'thing of the past,' cites benefits of AI investment boom

Warsh pledged Tuesday to "get monetary policy right" and defeat the inflation that has bedeviled the central bank for the past five years.

Will Renewed Middle East Tensions Benefit Cenovus' Upstream Business?

CVE, IMO, CNQ

CVE benefits from rising crude prices as well as its diversified upstream portfolio and production growth projects support enhanced cash flows.

Here's Why You Should Retain Reliance Stock in Your Portfolio

RS, SCCO, IDR, CSW

RS is riding strong end-market demand and acquisitions to fuel growth, even as weak chip and aerospace markets and aluminum costs pressure margins.

Here are Tuesday's biggest analyst calls: Nvidia, SK Hynix, Apple, SpaceX, Broadcom, AMD, Netflix & more

AMD, NVDA, NVDAN, NVDACL, AAPL, AAPLN, AAPLCL, AVGO, AVGON, AVGOCL, NFLX, NFLXN, NFLXCL, BROA, NVD, NVDD, 1NVDA, 4NVDA, 0R1I, 918422, NVDAUS, AAPLUS, AVGOUS, NFLXUS, SK

Here are the biggest calls on Wall Street on Tuesday.

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK, NBIX, ANAB, LQDA

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Loan Growth, Fee Income Strength to Support Truist's Q2 Earnings

TFC, USB, MTB

TFC's Q2 earnings are likely to have benefited from loan growth and stronger fee income, even as expenses and non-performing assets weigh on performance.